Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 13

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 13
---
 Phase 1b/2a
study, including the favorable safety and tolerability profile of AP-SA02, inform the design of a larger definitive efficacy study to
demonstrate superiority of AP-SA02 in treating complicated S. aureus bacteremia, and form the basis for an end-of-Phase 2 meeting
with the FDA which the Company plans to hold in the second half of 2025. We are committed to developing a superiority pivotal trial focused
on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilization of broad-spectrum antibiotics
and their detrimental impact on the normal human microbiome.

Additional Clinical Indications for AP-SA02

On
August 1, 2022, we announced FDA approval to proceed with our IND application for AP-SA02 in a second indication, prosthetic joint
infections (“PJI”) with S. aureus. We had planned to initiate a Phase 1b/2a trial; however, in light of the growing
concerns of both PJI and wound infections, we are considering revising the protocol to include both indications. Driven by data from the
bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability
of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic
joint infections and/or wound infections caused by S. aureus.

Corporate History and Reorganization

Armata was created as a result
of a business combination of AmpliPhi Biosciences Corporation, a bacteriophage development stage company (“AmpliPhi”) with
C3J Therapeutics, Inc. (“C3J”), where Ceres Merger Sub, Inc., a wholly-owned subsidiary of AmpliPhi, merged with
and into C3J (the “Merger”). On May 9, 2019, immediately prior to the closing of the Merger, AmpliPhi changed its name
to Armata Pharmaceuticals, Inc.

C3J’s predecessor, C3
Jian, Inc., was incorporated under the laws of the State of California on November 4, 2005. On February 26, 2016, as part
of a reorganization transaction, C3 Jian, Inc. merged with a wholly-owned subsidiary of C3J, and as part of this process, C3 Jian,